Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2018-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14737140.2018.1439744PMID 29429376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

  2019cited by this paper
• Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.

  2018cited by this paper
• PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.

  2018cited by this paper
• Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines

  2018cited by this paper
• Centralisation of radical cystectomies for bladder cancer in England, a decade on from the ‘Improving Outcomes Guidance’: the case for super centralisation

  2018cited by this paper
• Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature

  2017cited by this paper
• High Neutrophil‐to‐lymphocyte Ratio as Prognostic Factor in Patients Affected by Upper Tract Urothelial Cancer: A Systematic Review and Meta‐analysis

  2017cited by this paper
• Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?

  2017cited by this paper
• Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis

  2017cited by this paper
• Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

  2017cited by this paper
• Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy.

  2017cited by this paper
• Contemporary techniques and outcomes of robotic cystectomy and intracorporeal urinary diversions

  2017cited by this paper
• Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

  2017cited by this paper
• Prospects and progress of immunotherapy for bladder cancer

  2017influential reference
• Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

  2017influential reference
• Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database.

  2017cited by this paper
• The Rationale for Post-Operative Radiation in Localized Bladder Cancer

  2017cited by this paper
• Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.

  2017influential reference
• Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials

  2017cited by this paper
• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

  2017cited by this paper
• Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

  2017cited by this paper
• Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.

  2017cited by this paper
• Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy

  2017cited by this paper
• Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

  2017cited by this paper
• Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

  2017cited by this paper
• 866PImpact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC)

  2017cited by this paper
• Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

  2017cited by this paper
• 921TiPA Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)

  2017cited by this paper
• Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma

  2017cited by this paper
• Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase

  2016cited by this paper
• Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study.

  2016cited by this paper
• The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review.

  2016cited by this paper
• Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

  2016cited by this paper
• Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base.

  2016cited by this paper
• Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Systemic therapy for bladder cancer finally comes into a new age.

  2016cited by this paper
• Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.

  2016influential reference
• Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

  2016cited by this paper
• Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

  2016cited by this paper
• Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?

  2016cited by this paper
• A randomized clinical trial comparing adjuvant radiation versus chemo-RT versus chemotherapy alone after radical cystectomy for locally advanced bladder cancer.

  2016cited by this paper
• 1143 A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010)

  2016cited by this paper
• A phase 3 study of first-line durvalumab (MEDI4736) {+/-} tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.

  2016cited by this paper
• A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

  2015influential reference
• Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

  2015cited by this paper
• Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.

  2014cited by this paper
• B Cells and Ectopic Follicular Structures: Novel Players in Anti-Tumor Programming with Prognostic Power for Patients with Metastatic Colorectal Cancer

  2014cited by this paper
• Predictors of cancer‐specific mortality after disease recurrence following radical cystectomy

  2013cited by this paper
• Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

  2012cited by this paper
• Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

  2012cited by this paper
• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

  2012cited by this paper
• Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

  2011cited by this paper
• Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

  2011cited by this paper
• A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

  2011cited by this paper
• Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

  2010cited by this paper
• Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• The updated EAU guidelines on muscle-invasive and metastatic bladder cancer.

  2009cited by this paper
• Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer

  2009cited by this paper
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

  2009cited by this paper
• Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

  2009cited by this paper
• Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

  2007cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

  2006cited by this paper
• The role of perioperative chemotherapy in the treatment of urothelial cancer.

  2006cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

  2001cited by this paper
• Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control.

  1992cited by this paper
• INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS

  1976cited by this paper
• Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

  1976cited by this paper
• Cancer Management and Research Dovepress Survival Benefit of Adjuvant Radiotherapy in Stage Iii and Iv Bladder Cancer: Results of 170 Patients

  year unknowncited by this paper

• mRNA—From COVID-19 Treatment to Cancer Immunotherapy

  2023cites this paper
• Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study

  2022cites this paper
• Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics

  2022cites this paper
• Targeted Inhibition of O-Linked β-N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder

  2022cites this paper
• Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study.

  2021cites this paper
• Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer

  2020cites this paper
• Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer

  2020cites this paper
• Neoadjuvant chemotherapy before radical cystectomy: why we must adhere?

  2020cites this paper